Isomäki and Punnonen [36] indicated that in the active stage of RA, the level of anti-inflammatory cytokine IL-4 is too low, so it may not be able to counteract the harmful effects of proinflammatory cytokines. The gene discussed is IL4; the disease is rheumatoid arthritis.